APA (7th ed.) Citation

S, F., A, R., J, B., JS, C., Y, R., L, C., . . . MA, R. (2025). Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: A large, multicentre, observational, real-world study. The Lancet. Infectious diseases, 25(3), 301. https://doi.org/10.1016/S1473-3099(24)00570-X

Chicago Style (17th ed.) Citation

S, Fourati, et al. "Genotypic and Phenotypic Characterisation of Respiratory Syncytial Virus After Nirsevimab Breakthrough Infections: A Large, Multicentre, Observational, Real-world Study." The Lancet. Infectious Diseases 25, no. 3 (2025): 301. https://doi.org/10.1016/S1473-3099(24)00570-X.

MLA (9th ed.) Citation

S, Fourati, et al. "Genotypic and Phenotypic Characterisation of Respiratory Syncytial Virus After Nirsevimab Breakthrough Infections: A Large, Multicentre, Observational, Real-world Study." The Lancet. Infectious Diseases, vol. 25, no. 3, 2025, p. 301, https://doi.org/10.1016/S1473-3099(24)00570-X.